Johnson & Johnson’s Phase 4 STAR Study Of TREMFYA Meets Met Primary And Major Secondary Endpoints In Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
Benzinga Newsdesk 16 hours ago
News
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 studyTREMFYA
- TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study
- TREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffness
- TREMFYA was evaluated in first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation alongside patient-reported symptoms
NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). TREMFYA met primary and major secondary endpoints that demonstrated significant improvement in axial symptoms compared to placebo and significant reduction of MRI-assessed inflammation in the sacroiliac joints.1,a The Phase 4 STAR study is the first and only dedicated randomized, double-blind, placebo-controlled study designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement in PsA confirmed by magnetic resonance imaging (MRI). The late-breaking results are being presented at the Emirates Society for Rheumatology (ESR) Annual Meeting.
More on JNJ
Benzinga
Congressman Dumps Stocks for Treasury Note: Is This a Warning Sign?A recent trade by a member of Congress could signal a preference for Treasuries over stocks, which could be a trade to watch.

Analyst ratings Benzinga
JP Morgan Maintains Neutral on Johnson & Johnson, Raises Price Target to $300JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $285 to $300.
